Friday , 14 December 2018

4 Stocks With BIG Growth Prospects

Even in the current climate, savvy investors can still find promising stocks with big growth prospects…The stocks covered below all boast sales growth of over 20%, based on the Street’s 2019 estimates. These are the stocks to turn to if GDP growth begins to slow.

The original article has been edited here for length (…) and clarity ([ ])

Let’s take a closer look:

1. Facebook (Nasdaq:FB)

  • 2019 estimated sales growth 27%
  • Shares up 4.5% year-to-date

…Top RBC Capital analyst Mark Mahaney writes: “We still think FB is the best growth story in tech and we believe that FB’s current low market shares…will help it maintain premium growth for a long time.”

At the same time, FB still has several new large revenue growth drivers up its sleeve (Instagram monetization, Messaging Platform monetization, Camera/AR, AI and Video) and all this can be yours for a ‘highly reasonable’ valuation. Mahaney has a $250 price target on FB (36% upside potential). This comes out above the Street’s average price target as you can see below. Also note the 30 buy stock recommendations vs just 2 bearish calls:

(Click on image to enlarge)

2. Align Technology (Nasdaq:ALGN)

  • 2019 estimated sales growth 22%
  • Shares up 28% year-to-date

Align is a pioneer in teeth-straightening technology. You may have seen its popular “clear aligners” known as Invisalign. These removable transparent aligners are fast becoming a viable alternative to traditional metal braces.

Although other large dental providers are now trying to muscle in on the clear aligner space (think MMM, HSIC and XRAY), analysts aren’t too concerned. According to Piper Jaffray’s Matthew O’Brien these introductions were very much expected. He is skeptical about their impact on Align in the coming quarters but adds that a degree of caution will remain until their impact can be better assessed.

(Click on image to enlarge)

3. Amazon (Nasdaq:AMZN)

  • 2019 estimated sales growth 22%
  • Shares up 35% year-to-date

Amazon is firing on all cylinders. AMZN is both the leading online retailer as well as the e-commerce and fulfillment engine for most online retailers, and the leading provider of cloud infrastructure as a service to enterprise customers.

We believe AMZN’s innovative ability and growing market share will continue to drive increased revenue growth and significant cash flow” states top Tigress Financial analyst Ivan Feinseth. Plus “as long as AMZN continues to show strong growth in Net Sales Revenue and Economic Cash Flow we believe the market will continue to reward the shares with a higher valuation.”

Although Feinseth reiterated his Buy rating without a price target, we can see that the $1,859 average analyst price target indicates 18% upside from current levels. Note also AMZN’s very impressive score of 36 recent stock recommendations vs just 1 hold rating.

(Click on image to enlarge)

4. Autodesk (Nasdaq:ADSK)

  • 2019 estimated sales growth 27%
  • Shares up 30% year-to-date

This groundbreaking 3D design company makes software for people who make things. This includes software for architects, animators, constructors and engineers. Top Oppenheimer analyst Koji Ikeda calls ADSK his top stock pick in Saas/ Applications Software…and, looking forward, sees big growth potential as “the business is well positioned in a large but lightly penetrated construction industry that is yearning for next-generation technologies, like Autodesk’s, to help digitize the industry.”

Similarly, five-star Robert W Baird analyst Robert Oliver calls ADSK a “Fresh Pick.” He ramped up his price target from $145 to $155 (14% upside) while praising the company’s strong execution.

(Click on image to enlarge)

5. Vertex Pharmaceuticals (Nasdaq:VRTX)

  • 2019 estimated sales growth 22%
  • Shares up 4% year-to-date

Global biotech stock Vertex Pharmaceuticals Inc. boasts a growing portfolio of cystic fibrosis (CF) drugs. This is a genetic disorder that causes severe damage to the lungs, digestive system and other organs in the body.

The company has now launched its third CF drug Symdeko in the U.S., and management is anticipating EU approval in 2H18. “We continue to believe that VRTX’s dominance in the CF space, compelling bottom-line growth trajectory (43% CAGR through 2022), and significant free cash flow generation could potentially allow the company to substantially expand the breadth of its investor base” cheers JP Morgan’s Cory Kasimov.

Overall, this “strong buy” stock scored 9 recent bullish stock recommendations and just 1 hold rating. Five-star Cowen & Co analyst Phil Nadeau sees 28% upside potential and adds that “based on its prospects for strong long-term growth, VRTX remains a top large cap pick.” Meanwhile the average analyst price target suggests 20% upside from current share levels.

(Click on image to enlarge)

Scroll to very bottom of page & add your comments on this article. We want to share what you have to say!

Related Articles From the munKNEE Vault: 

1. These 5 Stocks Could Crush Q1 Earnings

Earnings for companies in the S&P 500 are expected to grow 17.3% in the first quarter, with sales up 10%. These rates represent the fastest pace of growth since the first quarter of 2011. In this article we have identified only 5 stocks that have a ‘Strong Buy’ and ‘Moderate Buy’ analyst consensus rating and notable upside from current prices.

2. These 10 “Graham Number” Stocks Should Be Great Investments

The following 10 companies have demonstrated strong financial positions through passing the rigorous requirements of the ModernGraham Investor and show potential for capital growth based on their current price in relation to intrinsic value. As such, these Graham Number stocks may be a great investment if they prove to be suitable for your portfolio after your own additional research.

3. The Solid Earnings Growth Of These 5 Stocks Should Result In Stupendous Returns

Earnings estimates embody analysts’ opinions of factors such as sales growth, product demand, competitive industry environment, profit margins and cost control. Thus, earnings estimates serve as a valuable tool while taking investment decisions. Earnings estimates also help analysts assess the cash flow to determine the fair value of a firm.

4. 5 Hot Stocks With Multiple Bullish Analyst Ratings

Which are the key stocks out there right now to boost your portfolio’s second quarter returns? All the 5 stocks below have a ‘Strong Buy’ analyst consensus rating. With that being said, let’s dive in and take a closer look at why these stocks have such a bullish analyst rating right now:

For the latest – and most informative – financial articles sign up (in the top right corner) for your FREE tri-weekly Market Intelligence Report newsletter (see sample here)

Support our work: like us on Facebook, follow us on Twitter, or share this article with a friend. munKNEE.com – the internet’s “most unique” financial site